Sandoz challenges key US patent for Ortho-Cyclen Lo
This article was originally published in Scrip
Executive Summary
Novartis's Sandoz unit has initiated a challenge to a key US patent, No 6,214,815, which covers Johnson & Johnson's Ortho Tri-Cyclen Lo (norgestimate plus ethinylestradiol), as the generics firm seeks to market a generic before the patent expires in December 2019.